In a study by Jan et al., forimtamig was superior to other BsAbs in T‐cell activation, cytokine production, and proliferation, especially when co‐cultured with MM with low expression of GPRC5D; the killing effect of forimtamig was stronger than that of conventional BsAbs with a 1:1 configuration targeting GPRC5D. This evidence concerns the gene GPRC5D and Miyoshi myopathy.